Janet Dancey

发表

Response assessment criteria for brain metastases: proposal from the RANO group.

Martin Bendszus, Riccardo Soffietti, Susan M. Chang, 2015, The Lancet. Oncology.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Eudocia Q Lee, Martin Bendszus, Gordon J Harris, 2018, The Lancet. Oncology.

Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials

Corneel Coens, Andrew Bottomley, Dongsheng Tu, 2018, Cancer.

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Yun Yen, Hedy L. Kindler, Regina Gandour-Edwards, 2009, Cancer Chemotherapy and Pharmacology.

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

Joseph L. Chin, John Trachtenberg, Lisa Wang, 2010, American journal of clinical oncology.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Mark T. W. Ebbert, Gina R. Petroni, Philip S. Bernard, 2012, Breast Cancer Research and Treatment.

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Scott E. Smith, Eric Lester, Theodore Karrison, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

Fiona A Miller, Robin Z Hayeems, Stephen Welch, 2013, European Journal of Human Genetics.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Robert Ford, Otto S Hoekstra, Yan Liu, 2016, European journal of cancer.

Clinical genomics information management software linking cancer genome sequence and clinical decisions.

Vincent Ferretti, John D McPherson, Ben Tran, 2013, Genomics.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Robert Ford, Otto S Hoekstra, Lawrence H Schwartz, 2017, The Lancet. Oncology.

Dose escalation trial designs based on a molecularly targeted endpoint

Edward L Korn, Sally Hunsberger, E. Korn, 2005, Statistics in medicine.

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Katherine S Panageas, Edi Brogi, Jacqueline F Bromberg, 2008, Clinical Cancer Research.

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Wolfgang Sadee, Charis Eng, Lai Wei, 2009, Clinical Cancer Research.

Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging

Janet Dancey, 2003 .